Tabelecleucel's third regulatory attempt hinges on whether updated ALLELE data satisfies FDA's reversed evidentiary standard for accelerated approval in EBV+ PTLD

Bull

A positive outcome requires the updated ALLELE dataset — with additional patients and extended follow-up — to demonstrate a durable and clinically meaningful overall response rate that clearly exceeds the pre-specified historical control benchmark, satisfying FDA's evidentiary standard for accelerated approval. If accepted, FDA grants accelerated approval for tabelecleucel in R/R EBV+ PTLD, triggering the $31M milestone from Pierre Fabre, validating the restructured partnership model, and establishing the first allogeneic EBV-specific T-cell therapy in a rare, high-unmet-need indication.

Bear

The most likely failure mode is that the updated ALLELE dataset, even with additional patients and longer follow-up, does not produce a response rate sufficiently above the historical control to satisfy FDA reviewers who have already reversed their position once, leaving the evidentiary bar ambiguous. A second CRL — potentially citing inadequate effect size, durability concerns, or residual CMC issues — would effectively end commercial prospects for tabelecleucel given Atara's minimal cash runway and near-total operational dependence on Pierre Fabre.